|本期目录/Table of Contents|

[1]罗敏涛,葛丽春,陈建鹏.瑞舒伐他汀联合依折麦布治疗老年糖尿病合并高脂血症的疗效及安全性分析[J].慢性病学杂志,2017,(12):1325-1327.
　LUO Min-tao,GE Li-chun,CHEN Jian-peng.Efficacy and safety of Rosuvastatin combined with Ezetimibe in the treatment ofeldlypatients with diabetes complicated with hyperlipidemia[J].,2017,(12):1325-1327.
点击复制

瑞舒伐他汀联合依折麦布治疗老年糖尿病合并高脂血症的疗效及安全性分析(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2017年12期
页码:
1325-1327
栏目:
论著
出版日期:
2018-01-02

文章信息/Info

Title:
Efficacy and safety of Rosuvastatin combined with Ezetimibe in the treatment ofeldlypatients with diabetes complicated with hyperlipidemia
作者:
罗敏涛; 葛丽春; 陈建鹏
深圳市南山区西丽人民医院社康部，广东深圳518055
Author(s):
LUO Min-tao;  GE Li-chun;  CHEN Jian-peng
Ministry of Health,Xili People's Hospital in Nanshan District, Shenzhen, Guangdong 518055, China Corresponding author: LUO Min-tao, E-mail: yanl1607@163.com
关键词:
糖尿病; 高脂血症; 瑞舒伐他汀; 依折麦布
Keywords:
Diabetes mellitus;  Hyperlipidemia;  Rosuvastatin;  Ezetimibe
分类号:
R587.1
DOI:
-
摘要:
目的针对老年糖尿病合并高脂血症患者采用瑞舒伐他汀联合依折麦布治疗后的临床疗效，并观察不良 反应发生情况。方法选取深圳市南山区西丽人民医院2013 年6 月—2015 年12 月收治的84 例老年糖尿病患 者，随机分为对照组及观察组，每组42例，两组均采用常规治疗，对照组在此基础上采用瑞舒伐他汀治疗，观察 组在对照组基础上采用依折麦布治疗。两组患者均治疗3 个月，观察治疗前后血脂、血糖变化，对比两组患者的 临床疗效和不良反应发生率。结果观察组临床疗效明显优于对照组，差异有统计学意义（P＜0.05）；两组患 者治疗前总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDLC） 和餐前血糖（FPG）、餐后2h 血糖（2hPG） 水平比较，差异无统计学意义（P＞0.05）；治疗后，两组患者的 上述指标均较治疗前明显改善（P＜0.05），且观察组较对照组明显（P＜0.05）。对照组不良反应发生率为 16.67%，观察组为11.90%，差异无统计学意义（P＞0.05）。结论瑞舒伐他汀联合依折麦布治疗老年糖尿病并 发高脂血症患者较单纯采用瑞舒伐他汀治疗的患者能有效的提高患者的疗效，安全性较高。
Abstract:
Objective To investigate the clinical efficacy of Rosuvastatin combined with Ezetimibe in elderly patients with diabetes mellitus complicated with hyperlipidemia and the incidence of adverse reactions. Methods A total of 84 cases of patients selected from Nanshan District Xili People's Hospita from June 2013to December2015were randomly divided into control group （n=42） and observation group （n=42） . On the basis of conventional therapy, control group were treated with Rosuvastatin treatment, the observation group received Ezetimibe treatment. Two groups of patients were all treated for 3 months. Blood Lipid and blood glucose changes were observed, and clinical efficacy were compared between the two groups. Results The clinical efficacy in observation group was significantly better than that in the control group （P<0.05） .There was no significant difference in the levels of TC, TG, LDL- C, HDL- C and FPG, 2hPG before treatment in the two groups （all P>0.05） . After treatment, the aboved indexes of the two groups were lower than those before treatment （all P< 0.05） , especially in the observation group （all P<0.05） . The incidence of adverse reactions in the control group was 16.67% , and the incidence of adverse reactions in the observation group was 11.91%, and there was no significant difference in the incidence of adverse reactions between the two groups （P>0.05） . Conclusions Clinical efficacy of Rosuvastatin combined with Ezetimibe was better than Rosuvastatin in treatment of elderly patients with diabetes mellitus complicated hyperlipidemia andcan effectively improve the efficacy and safety.

参考文献/References:

[1] 朱亚珅.瑞舒伐他汀联合依折麦布治疗老年糖尿病合并高脂血症 的疗效观察[J]. 中国医院用药评价与分析,2016,16(9):1183- 1185.
[2] 齐丽艳.关于糖尿病的新诊断标准与分型[J]. 求医问药(学术版), 2013,11(1):195.
[3] 陈红霞,刘如泉,黄秋菊,等. 依折麦布联合瑞舒伐他汀治疗老年 糖尿病并发高脂血症38例[J].医药导报,2014,33(2):216-218.
[4] 中华医学会内分泌学分会.中国成人2 型糖尿病预防的专家共识 [J].中华内分泌代谢杂志,2014,30(4):277-283.
[5] 方喜波,王宁,卢德媛,等.依折麦布联合瑞舒伐他汀在2型糖尿病 合并高脂血症患者中的疗效[J].中国循证心血管医学杂志,2015, 9(1):57-59,63.
[6] 李志杰,张文书.诺和力联合瑞舒伐他汀对2型糖尿病合并高脂血 症患者血糖、血脂干预效果[J]. 中国医药导报,2013,10(9):76- 78.
[7] 陈少萍.新型调脂药物依折麦布的临床应用[J].药学服务与研究, 2014,14(4):后插1-后插2.
[8] 邹云丞,吕云,白洁,等. 依折麦布联合小剂量阿托伐他汀钙对老 年冠心病患者颈动脉斑块的影响[J]. 中华老年心脑血管病杂志, 2016,18(5):464-466.
[9] 叶晓春.调脂治疗的新途径——依折麦布的研究进展[J]. 中国医 药导报,2010,7(15):11-12.

备注/Memo

备注/Memo:
作者简介：罗敏涛，本科，主治医师，研究方向：全科医学 通信作者：罗敏涛，E-mail: yanl1607@163.com
更新日期/Last Update: 2017-12-30